ClinicalTrials.gg
RecruitingNCT05350215Updated Jul 10, 2026

Atomoxetine and DAW2022 on OSA Severity

A Phase 1/2 interventional study of Placebo oral capsule and Atomoxetine Oral Capsule [Strattera] in Obstructive Sleep Apnea, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Brigham and Women's Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital — 12 open to participants now, 12 under way, none of them phase 3. Sleep Apnea, Obstructive · Brigham and Women's Hospital.

Planned enrollment
26th of 42
18 · median 22
Started
2022
with 2 others
Phase 1/2
13 of 42
7 open now
Primary completion
2026-12
later than 6 of 11 live
Registered
32nd of 42
by date

Among the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, this one is the 26th largest by planned enrollment, is one of 3 that started in 2022, is one of 13 in phase 1/2, reaches primary completion later than 6 of the 11 other live ones, and was the 32nd registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

12 of the 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Sleep Apnea, Obstructive by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. In previous research atomoxetine and oxybutynin showed promising effect at reducing OSA severity, however they reduced arousal threshold, one of the key traits responsible for OSA. Since oxybutynin was used mainly as a hypnotic, but it is burdened by several anti-cholinergic side effects, DAW2020, a hypnotic which prolonged the total sleep time in a previous trial in OSA patients, could be a better candidate to associate with atomoxetine.

Read the detailed description

Two overnight sleep studies will be performed: a drug night and a placebo night, with a month of washout between treatments. The patient will breath spontaneously (without CPAP) for both nights. On the study nights, subjects will present to the laboratory in the evening and be instrumented with a full polysomnography for monitoring sleep, physiological variables (endotypes), and respiratory events. A history and physical examination will be performed on each night prior to beginning the study, as will a urine pregnancy test in premenopausal women. The drugs will be administered as follows. There will be a 3-day run in of atomoxetine 40 mg followed by atomoxetine 80 mg starting on the fourth night until the night of the study. DAW2020 34 mg will be administered for 1-week to allow adequate plasma concentrations to be reached. For the sleep study, at least four hours of sleep (50% in the supine position) will be monitored to assess sleep and respiratory variables.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate-to-severe OSA (AHI ≥ 15 events/hr)

Exclusion criteria

Exclusion Criteria:

  • All participants will be healthy and without major organ system disease that would preclude undergoing the physiological measurements.
  • Use of medications expected to stimulate or depress respiration (including opioids, barbiturates, acetazolamide, doxapram, almitrine, theophylline, 4-hydroxybutanoic acid).
  • Use of SNRIs/SSRIs.
  • Conditions likely to affect OSA physiology: neuromuscular disease or other major neurological disorder, heart failure (also below), or any other unstable major medical condition.
  • Sleep disordered breathing or respiratory disorders other than obstructive sleep apnea:
  • Other sleep disorders: periodic limb movements (periodic limb movement arousal index > 10/hr), narcolepsy, or parasomnias.
  • to the study drug (angioedema or urticaria)
  • to DAW2020
  • Use of medications that lengthen
  • Hypokaliemia, hypomagnesemia, uncontrolled thyroid disease
  • Severe claustrophobia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (estimated)

Study arms

  • Placebo comparator
    Placebo oral capsules

    Placebo (2 pills) before sleep for a week

    Drug: Placebo oral capsule

  • Active comparator
    Atomoxetine and DAW2020 oral capsules

    DAW2020 34 mg 4 h before sleep, single night administration for a week. Simultaneous administration of atomoxetine 40 mg for 3 days 30 min before sleep, 80 mg for the following 4 days, 30 min before sleep

    Drug: Atomoxetine Oral Capsule [Strattera]

Interventions

  • DrugPlacebo oral capsule

    Placebo pills for a week, 1 pill 4 hr before sleep and 1 pill 30 min before sleep

  • DrugAtomoxetineStudies of AtomoxetineAtomoxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Atomoxetine for a week: 40 mg for 3 days 30 min before sleep, 80 mg for 4 days 30 min before sleep Simultaneous administration of DAW2020 for a week, 34 mg 4 h before sleep

    Also known as: DAW2020 Oral Capsule

06

What researchers measure

Primary outcomes

  1. Effect of atomoxetine and DAW2020 on OSA severity

    OSA severity will be quantified by the number of respiratory events/h (AHI)

    Time frame: 1 week

Secondary outcomes

  1. Effect of atomoxetine and DAW2020 on arousal index

    Arousal index will be calculated as the number of arousal per hour

    Time frame: 1 week

  2. Effect of atomoxetine and DAW2020 on nadir oxygen desaturation

    Nadir oxygen desaturation will be calculated as the lowest oxygen saturation value during sleep

    Time frame: 1 week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Messineo L, Preuss M, Azarbarzin A, Vena D, Gell L, Aishah A, Esmaeili N, Kim M, Burdick I, Chen T, White D, Sands SA, Wellman A. Effects of the Combination of Pimavanserin and Atomoxetine on OSA Severity: A Randomized Crossover Trial. Chest. 2025 Jul;168(1):223-235. doi: 10.1016/j.chest.2025.03.013. Epub 2025 Mar 28. PubMed 40158847 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2022
First posted
Apr 28, 2022
StartActual
Jun 1, 2022
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jul 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05350215
Responsible party
David Andrew Wellman (Associate Professor of Medicine, Brigham and Women's Hospital) — Principal investigator
First posted
Apr 28, 2022
Start date
Jun 1, 2022
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jul 10, 2026

Study contacts

Ludovico Messineo, MD, PhD
Contact
lmessineo@bwh.harvard.edu
18572726188

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atomoxetine

Start the discussion